The FDA’s view on the term probiotics, part 2: Further down the rabbit hole
By James Heimbach, Ph.D., F.A.C.N., JHEIMBACH LLC, Port Royal, VA A number of weeks ago I wrote on the ISAPP blog about US Food and Drug Administration (FDA) declining to file Generally Regarded As Safe (GRAS) notices that described the subject microorganism as a “probiotic” or “probiotic bacterium” (see The FDA’s view on the term […]